Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada
NCT Number: NCT00981552
A theoretical planning study to compare the normal tissue irradiation when using intensity modulated radiotherapy (IMRT) as opposed to standard radiotherapy for the definitive treatment of cervical cancer.
Looking for future studies?
Notify MeFemale
Interventional
Early Phase 1
Toronto, Ontario, Canada
Radiotherapy in combination with chemotherapy is the standard treatment of locally advanced cervix cancer, however with traditional techniques large volumes of bowel and bladder are irradiated causing short-term and long-term genito-urinary and gastro-intestinal side effects. IMRT has the potential to conform precisely to the target and spare normal tissues and reduce side effects. However because there are large dose gradients there is the potential to miss the target due to organ motion. Recent studies have documented organ motion and will be used to define the target. Approximately 60 planning scans, previously used to treat patients with cervix cancer, will be used to replan using an IMRT technique and differences in doses to tumour and normal tissues compared.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 6 months
Time frame: 6 months
Sunnybrook Health Sciences Centre
Other
Dosimetric Planning Study Comparing IMRT and 4-field Radiotherapy for Definitive Treatment of Cancer of the Cervix
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01325961
Anal Canal Cancers, Cervix Cancer
Paris, France
View Trial DetailsNCT04072913
Cervix Cancer, Communicable Diseases
Bordeaux, France
View Trial DetailsNCT06662435
Adnexal Diseases, Cervical Cancers
Chicago, Illinois, United States
View Trial DetailsNCT06263582
Carcinoma, Carcinoma in Situ
Kisumu, Kenya
View Trial Details